Voreloxin (SNS-595) is a topoisomerase II-targeting anticancer agent with broad-spectrum activity. It has demonstrated efficacy in preclinical in vitro and in vivo models against various cancers, including acute myeloid leukemia and solid tumors, supporting its research use in oncology and pharmacology studies.
Molekulargewicht:
401.44
CAS Nummer:
[175414-77-4]
Formel:
C18H19N5O4S
Target-Kategorie:
Apoptosis,Topoisomerase
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten